MML Investors Services LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 573,800 shares of the healthcare product maker’s stock after buying an additional 51,124 shares during the period. MML Investors Services LLC’s holdings in Abbott Laboratories were worth $71,891,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Mill Creek Capital Advisors LLC raised its stake in shares of Abbott Laboratories by 258.1% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 16,477 shares of the healthcare product maker’s stock worth $2,064,000 after buying an additional 11,876 shares during the last quarter. Minot DeBlois Advisors LLC raised its stake in shares of Abbott Laboratories by 1.7% during the fourth quarter. Minot DeBlois Advisors LLC now owns 11,951 shares of the healthcare product maker’s stock worth $1,497,000 after buying an additional 196 shares during the last quarter. Focus Partners Wealth raised its stake in shares of Abbott Laboratories by 197.0% during the fourth quarter. Focus Partners Wealth now owns 1,576,873 shares of the healthcare product maker’s stock worth $197,567,000 after buying an additional 1,045,870 shares during the last quarter. Graybill Wealth Management LTD. raised its stake in shares of Abbott Laboratories by 2.3% during the fourth quarter. Graybill Wealth Management LTD. now owns 55,231 shares of the healthcare product maker’s stock worth $6,920,000 after buying an additional 1,256 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Abbott Laboratories by 40.3% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 875,340 shares of the healthcare product maker’s stock worth $109,671,000 after buying an additional 251,441 shares during the last quarter. 75.18% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group dropped their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Evercore lowered their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research note on Wednesday, April 22nd. Piper Sandler lowered their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.38.
Insider Buying and Selling at Abbott Laboratories
In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by corporate insiders.
Abbott Laboratories News Summary
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
- Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
- Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
- Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
- Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
- Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
- Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
- Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
- Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories
Abbott Laboratories Stock Down 0.3%
Shares of ABT stock opened at $87.89 on Monday. The firm has a fifty day moving average of $91.46 and a 200-day moving average of $107.84. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The company has a market capitalization of $153.08 billion, a price-to-earnings ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the firm earned $1.09 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.9%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
